CELL: Fudan University's Yu Jia team has revealed a single-celled landscape of early recurrence of liver cancer

Liver cancer is the fourth leading cause of cancer-related deaths among the world.
(HCC) is the most important form of liver cancer, accounting for 75%-85% of patients.
for liver cancer, surgical excision is currently the most effective treatment, with healing potential.
, however, the high incidence of tumor recurrence (50-70% 5 years after surgery) hinders the improvement of survival.
addition, early recurrence within 2 years of surgery accounts for 70% of relapsed HCC cases, which are rarely treatable and associated with poor survival.
, we still know very little about the molecular mechanisms associated with rapid recurrence of liver cancer after surgery.
further exploration of tumor recurrence can improve our understanding of the mechanisms associated with tumor recurrence and progress, and help identify more effective HCC treatment strategies, including immunotherapy.
recently, Yu Jia and her team from Fudan University analyzed transcription groups of 17,000 cells in 18 primary or early recurrence HCC cases.
in two separate cohorts, the regulatory T-cell levels of early recurrence tumors decreased, degenerative cells (DCs) increased, and immersive CD8-T cells increased.
It is worth noting that CD8-T cells in relapsed tumors overexploit KLRB1 (CD161) and exhibit congenital low cytotoxicity and low cloning dilation, which is different from the classical depletion observed in primary HCC.
studies have shown that the abundance of these cells is associated with poor prognostics.
differential gene expression and interaction analysis revealed the potential immune escape mechanism of recurring tumor cells, which inhibits DC antigen delivery and recruits congenital CD8-T cells.
, the study's comprehensive description of the HCC ecosystem provides a deeper insight into the mechanisms of immune escape associated with tumor recurrence.
。